Re-irradiation for painful bone metastases: evidence-based approach
Carregando...
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2015
Editora
AME PUBL CO
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
CHIU, Nicholas
CHIU, Leonard
POPOVIC, Marko
DEANGELIS, Carlo
LUTZ, Stephen
ZHANG, Na
LECHNER, Breanne
PULENZAS, Natalie
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
ANNALS OF PALLIATIVE MEDICINE, v.4, n.4, p.214-219, 2015
Resumo
The prognosis of patients with bone metastases has improved with the advent of increasingly effective systemic treatment and better supportive care. A growing number of bone metastases patients now outlive the duration of benefits from their initial treatment of radiotherapy (RT) while some patients fail to initially respond to RT. As such, re-irradiation (re-RT) may be required. The current review updates the literature on findings in the area of re-RT. In particular, the recent publication of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Symptom Control (SC20) trial shows that an 8 Gy treatment in a single fraction for re-RT is non-inferior and less toxic than 20 Gy in multiple fractions. Furthermore, patients responding to re-RT have experienced superior quality of life (QoL) and complain of less functional interference from pain; this provides a strong case in support of bone metastases patients being offered re-treatment. However, despite such findings, some specific patients will never respond to initial radiation or re-RT. New evidence suggests significant differences in bone markers between responders and non-responders, thus opening the possibility for further research into the use of such biomarkers for predicting prognosis and for the guidance of consequent treatment decisions.
Palavras-chave
Re-irradiation (re-RT), bone metastases
Referências
- Bedard G, 2014, RADIOTHER ONCOL, V112, P125, DOI 10.1016/j.radonc.2014.06.015
- Chow E, 2006, CLIN ONCOL-UK, V18, P125, DOI 10.1016/j.clon.2005.11.014
- Chow E, 2012, CLIN ONCOL-UK, V24, P112, DOI 10.1016/j.clon.2011.11.004
- Chow E, 2015, RADIOTHER ONCOL, V115, P141, DOI 10.1016/j.radonc.2015.02.025
- Chow E, 2014, J CLIN ONCOL, V32, P3867, DOI 10.1200/JCO.2014.57.6264
- Chow E, 2014, LANCET ONCOL, V15, P164, DOI 10.1016/S1470-2045(13)70556-4
- Hoskin PJ, 2000, LANCET, V355, P1428, DOI 10.1016/S0140-6736(00)02144-9
- Huisman M, 2012, INT J RADIAT ONCOL, V84, P8, DOI 10.1016/j.ijrobp.2011.10.080
- Jeremic B, 1999, RADIOTHER ONCOL, V52, P123, DOI 10.1016/S0167-8140(99)00108-5
- Jeremic B, 2002, J PAIN SYMPTOM MANAG, V23, P26, DOI 10.1016/S0885-3924(01)00366-9
- Jeremic B, 1998, INT J RADIAT ONCOL, V42, P161, DOI 10.1016/S0360-3016(98)00174-6
- Mercadante S, 1997, PAIN, V69, P1, DOI 10.1016/S0304-3959(96)03267-8
- MITHAL NP, 1994, INT J RADIAT ONCOL, V29, P1011
- UPPELSCHOTEN JM, 1995, RADIOTHER ONCOL, V36, P198, DOI 10.1016/0167-8140(95)01587-7
- Wong E, 2014, RADIOTHER ONCOL, V110, P61, DOI 10.1016/j.radonc.2013.09.004